

CITATION REPORT

List of articles citing

Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology

DOI: 10.1016/j.neulet.2005.11.012

Neuroscience Letters, 2006, 396, 67-72.

Source: <https://exaly.com/paper-pdf/39906045/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1066	Diagnosis and treatment of Parkinson disease: molecules to medicine. 2006 , 116, 1744-54		461
1065	Predicting Parkinson's disease: worthwhile but are we there yet?. 2006 , 6, 272-277		10
1064	Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. 2007 , 68, 2012-8		167
1063	Beating a dead horse: dopamine and Parkinson disease. 2007 , 69, 1701-11		101
1062	Patient-reported autonomic symptoms in Parkinson disease. 2007 , 69, 333-41		232
1061	Gastrointestinale Störungen bei Morbus Parkinson. 2007 , 34, 6-10		
1060	Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. 2007 , 69, 2093-104		171
1059	Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. 2007 , 16, 651-66		59
1058	Parkinson Disease: Molecular Insights. 2007 , 221-239		
1057	Neuronal death: where does the end begin?. 2007 , 30, 159-66		118
1056	The premotor phase of Parkinson's disease. 2007 , 13 Suppl, S2-7		106
1055	Innervation of the gastrointestinal tract: patterns of aging. 2007 , 136, 1-19		172
1054	Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. 2007 , 207, 4-12		158
1053	Olfaction in Parkinson's disease. 2007 , 13 Suppl 3, S225-8		58
1052	Guidelines on the irritable bowel syndrome: mechanisms and practical management. 2007 , 56, 1770-98		564
1051	Current Concepts on the Etiology and Pathogenesis of Parkinson Disease. 2007 , 105-127		
1050	Bowel movement frequency in late-life and incidental Lewy bodies. 2007 , 22, 1581-6		176

1049	Dysautonomia and cognitive dysfunction in Parkinson's disease. 2007 , 22 Suppl 17, S374-8	45
1048	Parkinson's disease: a dual-hit hypothesis. 2007 , 33, 599-614	561
1047	Classical Parkinson disease versus Parkinson complex--reflections against staging and in favour of heterogeneity. 2007 , 14, 721-8	23
1046	High and complementary expression patterns of alcohol and aldehyde dehydrogenases in the gastrointestinal tract: implications for Parkinson's disease. 2007 , 274, 1212-23	26
1045	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. 2007 , 17, 118-21	77
1044	Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. 2007 , 113, 421-9	257
1043	On the key role played by altered protein conformation in Parkinson's disease. 2008 , 115, 1285-99	5
1042	Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. 2008 , 115, 437-44	283
1041	Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. 2008 , 23, 1085-92	144
1040	Neural control of the gastrointestinal tract: implications for Parkinson disease. 2008 , 23, 1065-75	151
1039	Do Parkinson's disease and dementia with Lewy bodies differ by route of environmental precipitant?. 2008 , 23, 1617	1
1038	The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it?. 2008 , 23, 1799-807	98
1037	Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. 2008 , 153, 634-44	58
1036	Neuropathology of Parkinson's Disease. 2008 , 35-48	4
1035	Neuroanatomy and Pathology of Sporadic Parkinson's Disease. 2008 ,	2
1034	Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?. 2008 , 153, 733-50	136
1033	Design of clinical trials of gene therapy in Parkinson disease. 2008 , 209, 41-7	11
1032	The role of MPTP in Parkinson's disease: connecting brain and gut?. 2008 , 210, 281-5	6

1031	Invited Article: Nervous system pathology in sporadic Parkinson disease. 2008 , 70, 1916-25	410
1030	Complex I Inhibition, Rotenone and Parkinson's Disease. 2008 , 195-206	
1029	Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. 2008 , 131, 642-50	346
1028	Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. 2008 , 36, 289-310	566
1027	CORRECTION. 2008 , 57, 1743-1743	
1026	ANSWER. 2008 , 57, 1743-1744	2
1025	Pathological lesions in colonic biopsies during Parkinson's disease. 2008 , 57, 1741-3	159
1024	Irregular gastrointestinal drug absorption in Parkinson's disease. 2008 , 4, 193-203	74
1023	Managing the Non-Motor Symptoms of Parkinson's Disease. 2008 , 91-120	1
1022	Neurodegenerative diseases that affect olfaction. 153-214	
1021	Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. 2009 ,	
1020	Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. 2009 ,	
1019	Treatment strategies for nonmotor manifestations of Parkinson's disease. 2009 , 10, 773-84	8
1018	Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study. 2009 , 5, 531-2	10
1017	Parkinson disease: extranigral, multisystem, and {alpha}-synuclein "plus". 2009 , 66, 914-5; author reply 915-6	5
1016	Parkinson Disease: Extranigral, Multisystem, and {alpha}-Synuclein PlusReply. 2009 , 66, 910	1
1015	Medical records documentation of constipation preceding Parkinson disease: A case-control study. 2009 , 73, 1752-8	260
1014	Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. 2009 , 36, 96-102	167

1013	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. 2009 , 8, 1150-7	567
1012	Lesions outside the CNS in Parkinson's disease. 2009 , 24, 793-800	56
1011	Gastric myoelectrical differences between Parkinson's disease and multiple system atrophy. 2009 , 24, 1579-86	18
1010	Bowel movement frequency in late-life and substantia nigra neuron density at death. 2009 , 24, 371-6	53
1009	When does Parkinson's disease begin?. 2009 , 24 Suppl 2, S656-64	93
1008	Major nutritional issues in the management of Parkinson's disease. 2009 , 24, 1881-92	144
1007	Hybrid cars may interfere with implanted deep brain stimulators. 2009 , 24, 2290-1	2
1006	Deep brain stimulation in acute management of status dystonicus. 2009 , 24, 2291-2	39
1005	Plasma phenylalanine level in dopa-responsive dystonia. 2009 , 24, 2289-90	2
1004	Incidental Lewy body disease restricted to the heart and stellate ganglia. 2009 , 24, 2299-301	48
1003	Restless legs syndrome as an initial manifestation of metastatic conus medullaris lesion. 2009 , 24, 2294-6	0
1002	Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. 2009 , 24, 2293-4	55
1001	Eating dystonia. 2009 , 24, 2303-4	0
1000	Giant somatosensory evoked potential in a patient with shaking TIA. 2009 , 24, 2301-3	4
999	Unilateral periodic limb movements: is this a pointer for atypical presentation of corticobasal degeneration syndrome?--A case report. 2009 , 24, 2298-9	4
998	Paraneoplastic chorea associated with breast cancer. 2009 , 24, 2296-7	7
997	Complex movement disorders in a sporadic Boucher-Neuhüser Syndrome: Phenotypic manifestations beyond the triad. 2009 , 24, 2304-6	8
996	Opsoclonus myoclonus syndrome in the context of Salmonellosis. 2009 , 24, 2306-8	10

995	Plasticity and neural stem cells in the enteric nervous system. 2009 , 292, 1940-52	44
994	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. 2009 , 117, 613-34	433
993	Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. 2009 , 1, 20	19
992	Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. 2009 , 21, 215-22	65
991	The second brain and Parkinson's disease. 2009 , 30, 735-41	142
990	Parkinson's disease: the dual hit theory revisited. 2009 , 1170, 615-22	173
989	Neuropathology of Lewy body disorders. 2009 , 80, 203-10	44
988	The cybrid model of sporadic Parkinson's disease. 2009 , 218, 320-5	40
987	Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. 2009 , 218, 154-61	116
986	Hyposialorrhea as an early manifestation of Parkinson disease. 2009 , 150, 150-1	31
985	Abnormal serum concentrations of proteins in Parkinson's disease. 2009 , 389, 321-7	17
984	Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. 2009 , 15, 516-20	52
983	Evaluation of gastric emptying in familial and sporadic Parkinson disease. 2009 , 15, 692-6	31
982	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. <i>Neuroscience Letters</i> , 2009 , 467, 203-7	3-3 58
981	Recognition and management of Parkinson's disease during the premotor (prodromal) phase. 2009 , 9, 847-57	11
980	Diagnosis and the premotor phase of Parkinson disease. 2009 , 72, S12-20	161
979	Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. 2009 , 220, 109-19	47
978	Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. 2009 , 220, 374-82	27

977	Neuropathology of non-motor features of Parkinson disease. 2009 , 15 Suppl 3, S1-5	197
976	Non-motor extranigral signs and symptoms in Parkinson's disease. 2009 , 15 Suppl 3, S6-12	82
975	Parkinson's disease. 2009 , 373, 2055-66	1541
974	Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. 2009 , 15, 157-82	29
973	Les biopsies coliques obtenues par endoscopie : un outil pour étudier l'atteinte du système nerveux entérique dans la maladie de Parkinson. 2009 , 165, S9-S10	
972	Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. 2009 , 66, 1114-9	30
971	Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. 2009 , 66, 742-50	113
970	The Parkinson chimera. 2009 , 72, S2-11	49
969	Maladie de Parkinson idiopathique : aspects cliniques, diagnostiques et thérapeutiques. 2010 , 7, 1-30	
968	Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system. 2010 ,	15
967	The regulatory functions of the brain: From genome to organism. 2010 , 80, 199-207	
966	Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. 2010 , 15, 279-94	51
965	Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. 2010 , 119, 689-702	594
964	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. 2010 , 119, 703-13	215
963	alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells. 2010 , 119, 723-35	71
962	Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. 2010 , 120, 1-12	106
961	Enteric nervous system in the small intestine: pathophysiology and clinical implications. 2010 , 12, 358-65	77
960	Are synucleinopathies prion-like disorders?. 2010 , 9, 1128-38	191

959	Response times for visually guided saccades in persons with Parkinson's disease: a meta-analytic review. 2010 , 48, 887-99	49
958	Neuroimaging for Lewy body disease: is the in vivo molecular imaging of β -synuclein neuropathology required and feasible?. 2010 , 65, 28-55	35
957	Evidence in favor of Braak staging of Parkinson's disease. 2010 , 25 Suppl 1, S78-82	101
956	Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. 2010 , 25 Suppl 1, S94-7	22
955	The nonmotor symptoms of Parkinson's disease--an overview. 2010 , 25 Suppl 1, S123-30	103
954	Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease. 2010 , 25, 623-8	28
953	Gray matter correlations of cognition in incident Parkinson's disease. 2010 , 25, 629-33	52
952	Carisbamate in essential tremor: brief report of a proof of concept study. 2010 , 25, 634-8	15
951	Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. 2010 , 25, 638-42	30
950	Incidental Lewy body disease: clinical comparison to a control cohort. 2010 , 25, 642-6	89
949	Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson's disease. 2010 , 25, 1847-52	18
948	Anxious personality predicts an increased risk of Parkinson's disease. 2010 , 25, 2105-13	98
947	The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease. 2010 , 25, 2361-8	74
946	β -Synuclein expression is induced by depolarization and cyclic AMP in enteric neurons. 2010 , 115, 694-706	21
945	Are dysautonomic and sensory symptoms present in early Parkinson's disease?. 2010 , 122, 72-7	7
944	Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. 2010 ,	4
943	Biopsable neural tissues: toward new biomarkers for Parkinson's disease?. 2010 , 1, 128	28
942	Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. 2010 , 5, e8762	348

941	Cortical and subcortical disorders. 167-186	
940	Parkinson's disease. 187-205	3
939	Seniors with Parkinson's disease: initial medical treatment. 2010 , 6, 159-66	3
938	When does Parkinson disease start?. 2010 , 67, 798-801	187
937	Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. 2010 , 19, 1633-50	198
936	[Olfactory dysfunction in parkinsonian syndromes. Its role in early and differential diagnosis]. 2010 , 78, 483-9; quiz 490-3	
935	Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici. 2010 , 10, 1-29	
934	Nonmotor Aspects of Parkinson's Disease. 2010 , 34, 229-251	6
933	Gastrointestinal dysfunction in Parkinson's Disease. 2010 , 289, 69-73	152
932	Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. 2010 , 293, 82-6	96
931	Quantification of β -synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. 2010 , 4, 683-99	101
930	Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. <i>Neuroscience Letters</i> , 2010 , 469, 357-9	3-3 84
929	Age-related changes in vagal afferents innervating the gastrointestinal tract. 2010 , 153, 90-8	33
928	Behavioral phenotyping of mouse models of Parkinson's disease. 2010 , 211, 1-10	116
927	A timeline for Parkinson's disease. 2010 , 16, 79-84	369
926	Cardiac ¹²³ I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. 2010 , 16, 252-5	82
925	Are hiccups non-motor symptoms?. 2010 , 16, 690	2
924	The propagation of prion-like protein inclusions in neurodegenerative diseases. 2010 , 33, 317-25	336

923	Pupil light reflex in Parkinson's disease: evaluation with pupillometry. 2011 , 121, 37-43	45
922	Synuclein deposition and non-motor symptoms in Parkinson disease. 2011 , 310, 107-11	73
921	View point: etiology in Parkinson's disease. Dual hit or spreading intoxication. 2011 , 310, 9-11	47
920	Progress in defining the premotor phase of Parkinson's disease. 2011 , 310, 4-8	41
919	Anorectal dysfunctions in Parkinson's disease. 2011 , 310, 144-51	17
918	Peripheral Lewy body pathology in Parkinson's disease and incidental Lewy body disease: four cases. 2011 , 310, 100-6	18
917	Treatment approaches of gastrointestinal dysfunction in Parkinson's disease, therapeutical options and future perspectives. 2011 , 310, 152-8	15
916	Handbook of Non-Motor Symptoms in Parkinson's Disease. 2011 ,	5
915	Gastrointestinal dysfunction in Parkinson's disease. 2011 , 17, 10-5	200
914	Authors' replies to the comments of Giugni et al. on "Hiccups in Parkinson's disease: an overlooked non-motor symptom?". 2011 , 17, 653	
913	Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?. 2011 , 32, 857-63	109
912	Gastrointestinal Symptoms. 2011 , 85-89	
911	Trastornos autonómicos en enfermedad de Parkinson. 2011 , 139, 100-106	1
910	Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice. 2011 , 20, 181-8	33
909	Colonic neuropathology is independent of olfactory dysfunction in Parkinson's disease. 2011 , 1, 389-94	5
908	Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's disease. 2011 , 17, 5035-48	44
907	Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. 2011 , 2011, 708404	43
906	Toxin-induced and genetic animal models of Parkinson's disease. 2010 , 2011, 951709	42

905	Gastrointestinal symptoms in Parkinson disease: clinical aspects and management. 2011 , 38, 557-64	11
904	Parallel manifestations of neuropathologies in the enteric and central nervous systems. 2011 , 23, 1056-65	47
903	Transfer of host-derived β synuclein to grafted dopaminergic neurons in rat. 2011 , 43, 552-7	140
902	[Neurological applications of the ^{123}I -MIBG myocardial innervation scintigraphy]. 2011 , 30, 197-204	1
901	CSF β synuclein, tau, and amyloid β in Parkinson's disease [Authors' reply]. 2011 , 10, 681-683	3
900	Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease. 2011 , 1420, 59-67	61
899	Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the ^{13}C -acetate breath test. 2011 , 258, 421-6	60
898	Reduced bowel sounds in Parkinson's disease and multiple system atrophy patients. 2011 , 21, 181-4	13
897	The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. 2011 , 26, 653-8	107
896	Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. 2011 , 26, 889-92	115
895	A reappraisal of long-latency abdominal muscle reflexes in patients with propriospinal myoclonus. 2011 , 26, 1759-63	5
894	Electrogastrographyc activity in Parkinson's disease patients with and without motor fluctuations. 2011 , 26, 1737-40	1
893	Late-onset asymmetric myoclonus: an emerging syndrome. 2011 , 26, 1744-8	3
892	Tongue control for swallowing in Parkinson's disease: effects of age, rate, and stimulus consistency. 2011 , 26, 1725-9	19
891	Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. 2011 , 26, 1729-32	15
890	Subthreshold depression in Parkinson's disease. 2011 , 26, 1741-4	11
889	Dystonia due to cerebral palsy responds to deep brain stimulation of the globus pallidus internus. 2011 , 26, 1748-51	68
888	The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from southern Italy. 2011 , 26, 1733-6	16

887	Diffusion tensor magnetic resonance imaging tractography in progressive supranuclear palsy. 2011 , 26, 1752-5	31
886	Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. 2011 , 26, 1756-9	106
885	Genetic variants of β synuclein are not associated with essential tremor. 2011 , 26, 2552-6	12
884	Temporal stability of the Unified Dyskinesia Rating Scale. 2011 , 26, 2556-9	15
883	Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the ^{13}C -octanoate breath test. 2011 , 26, 2559-63	22
882	Reproductive factors and Parkinson's disease: a multicenter case-control study. 2011 , 26, 2563-6	26
881	Camptocormia in Japanese patients with Parkinson's disease: a multicenter study. 2011 , 26, 2567-71	35
880	Cell transplantation and gene therapy in Parkinson's disease. 2011 , 78, 126-58	31
879	Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. 2011 , 70, 532-40	452
878	Meilensteine im Verlauf des Idiopathischen Parkinson-Syndroms. 2011 , 38, 520-524	0
877	Rotenone, paraquat, and Parkinson's disease. 2011 , 119, 866-72	804
876	Parkinson disease: the enteric nervous system spills its guts. 2011 , 77, 1761-7	93
875	A prospective study of bowel movement frequency and risk of Parkinson's disease. 2011 , 174, 546-51	73
874	Pupillometry and ^{123}I -DaTSCAN imaging in Parkinson's disease: a comparison study. 2012 , 122, 26-34	11
873	Intracerebral inoculation of pathological β synuclein initiates a rapidly progressive neurodegenerative β synucleinopathy in mice. 2012 , 209, 975-86	727
872	Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex. 2012 , 2, 67-76	36
871	Altered pharyngeal muscles in Parkinson disease. 2012 , 71, 520-30	92
870	Lower Brainstem Regulation of Visceral, Cardiovascular, and Respiratory Function. 2012 , 1058-1073	5

869	[Gastrointestinal dysfunction in idiopathic Parkinson's disease]. 2012 , 83, 1282-91	8
868	Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. 2012 , 124, 665-80	138
867	Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. 2012 , 74, 80-90	71
866	Does a prion-like mechanism play a major role in the apparent spread of β synuclein pathology?. 2012 , 4, 48	5
865	Die Hyperkonnektivität wird reduziert. 2012 , 14, 36-37	
864	[Enteric nervous system and Parkinson's disease]. 2012 , 33, 335-8	3
863	Non-motor symptoms of Parkinson's disease in China: a review of the literature. 2012 , 18, 446-52	32
862	Can Parkinson's disease pathology be propagated from one neuron to another?. 2012 , 97, 205-19	83
861	Spinal cord lesions in sporadic Parkinson's disease. 2012 , 124, 643-64	113
860	Role of Peripheral and Brain-Derived Dopamine (DA) in Immune Regulation. 2012 , 3, 111-155	11
859	Distinct mechanisms of axonal globule formation in mice expressing human wild type β synuclein or dementia with Lewy bodies-linked P123H β synuclein. 2012 , 5, 34	13
858	Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. 2012 , 4, 12	37
857	Expression pattern and localization of alpha-synuclein in the human enteric nervous system. 2012 , 48, 474-80	89
856	Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology. 2012 , 2, 167-170	2
855	From β synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. 2012 , 1476, 183-202	75
854	Autonomic involvement in Parkinson's disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. 2012 , 313, 57-63	97
853	Parkinson's disease: acquired frailty of archaic neural networks?. 2012 , 314, 143-51	15
852	[Autonomic nervous system as a source of biomarkers in Parkinson's disease]. 2012 , 41, 695-701	2

851	Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. 2012 , 2, 898	255
850	Parkinson's disease. 2012 , 65, 389-455	184
849	Chloridkanalaktivator l�st die Verstopfung. 2012 , 14, 37-37	
848	When does Parkinson's disease begin? From prodromal disease to motor signs. 2012 , 168, 809-14	33
847	�synuclein in Parkinson's disease. 2012 , 2, a009399	625
846	Animal Models of Parkinson's Disease Induced by Toxins and Genetic Manipulation. 2012 ,	
845	Pulsed wave Doppler ultrasound is useful to assess vasomotor response in patients with multiple system atrophy and well correlated with tilt table study. 2012 , 2012, 548529	1
844	Taming the Irritable Bowel. 2012 , 19, 142-156	
843	Anorectal manometric dysfunctions in newly diagnosed, early-stage Parkinson's disease. 2012 , 8, 184-9	14
842	Toward a redefinition of Parkinson's disease. 2012 , 27, 54-60	132
841	Lewy pathology and neurodegeneration in premotor Parkinson's disease. 2012 , 27, 597-607	110
840	Premotor Parkinson's disease: concepts and definitions. 2012 , 27, 608-16	108
839	Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. 2012 , 27, 716-9	295
838	A colonic biomarker of Parkinson's disease?. 2012 , 27, 674-6	6
837	Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. 2012 , 78, 1650-4	74
836	Autonomic dysfunction in Parkinson's disease. 2012 , 12, 697-706	30
835	Interaction between pathogenic proteins in neurodegenerative disorders. 2012 , 16, 1166-83	89
834	A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. 2012 , 9, 297-314	181

833	Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus. 2012 , 47, 15-25	47
832	βSynuclein in the olfactory system of a mouse model of Parkinson's disease: correlation with olfactory projections. 2012 , 217, 447-58	23
831	Pale neurites, premature βSynuclein aggregates with centripetal extension from axon collaterals. 2012 , 22, 67-78	46
830	A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. 2012 , 45, 305-9	106
829	Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. 2012 , 46, 559-64	178
828	Neurochemistry and the non-motor aspects of PD. 2012 , 46, 508-26	66
827	Olfaction in Parkinson's disease and related disorders. 2012 , 46, 527-52	279
826	Animal models of the non-motor features of Parkinson's disease. 2012 , 46, 597-606	113
825	βSynuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. 2012 , 47, 258-67	68
824	Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. 2012 , 48, 9-19	58
823	Voltage-gated calcium channels and Parkinson's disease. 2012 , 133, 324-33	25
822	The role of βSynuclein in neurodegeneration [An update. 2012 , 3,	12
821	A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. 2012 , 24, e202-5	63
820	Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. 2012 , 24, e425-36	67
819	Phosphorylated βSynuclein immunoreactivity in the posterior pituitary lobe. 2012 , 32, 385-9	11
818	Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. 2012 , 27, 709-15	292
817	Neuronal vulnerability, pathogenesis, and Parkinson's disease. 2013 , 28, 41-50	121
816	Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. 2013 , 28, 237-40	86

815	Parkinson's Disease and Nonmotor Dysfunction. 2013 ,	3
814	Parkinson disease and sleep: sleep-wake changes in the premotor stage of Parkinson disease; impaired olfaction and other prodromal features. 2013 , 13, 373	18
813	Role of enteric glial cells in gastric motility in diabetic rats at different stages. 2013 , 33, 496-500	11
812	The prion hypothesis in Parkinson's disease: Braak to the future. 2013 , 1, 2	155
811	The role of small intestinal bacterial overgrowth in Parkinson's disease. 2013 , 28, 1241-9	194
810	Neuronal vulnerability, pathogenesis, and Parkinson's disease. 2013 , 28, 715-24	105
809	Epidemiology and Clinical Diagnosis of Parkinson Disease. 2013 , 8, 447-58	5
808	Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease. 2013 , 68, 235-72	22
807	Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. 2013 , 260, 1332-8	175
806	Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. 2013 , 125, 491-511	102
805	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. 2013 , 241, 148-55	32
804	Epilepsy: shining a light on seizure control-optogenetic approach shows promise for treatment and prevention of epilepsies. 2013 , 9, 1	2
803	100 years of Lewy pathology. 2013 , 9, 13-24	691
802	Inflammation and α -synuclein's prion-like behavior in Parkinson's disease--is there a link?. 2013 , 47, 561-74	148
801	Le syst�me nerveux ent�rique : une fen�tre sur l'atteinte du syst�me nerveux central dans la maladie de Parkinson. 2013 , 4, 229-232	
800	Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem. 2013 , 31, S1-16	34
799	Sympathetic axonopathies and hyperinnervation in the small intestine smooth muscle of aged Fischer 344 rats. 2013 , 179, 108-21	7
798	The Lewy body in Parkinson's disease and related neurodegenerative disorders. 2013 , 47, 495-508	205

797	Parkinson disease: from pathology to molecular disease mechanisms. 2013 , 62, 132-144	417
796	βSynuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. 2013 , 47, 484-94	40
795	The role of inflammation in sporadic and familial Parkinson's disease. 2013 , 70, 4259-73	124
794	Glutathione metabolism and Parkinson's disease. 2013 , 62, 13-25	276
793	Activity-dependent secretion of alpha-synuclein by enteric neurons. 2013 , 125, 512-7	65
792	Effects of oral administration of rotenone on gastrointestinal functions in mice. 2013 , 25, e183-93	51
791	Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease. 2013 , 13, 695-705	8
790	Colonic inflammation in Parkinson's disease. 2013 , 50, 42-8	343
789	Foveal vision is impaired in Parkinson's disease. 2013 , 19, 1-14	49
788	Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. 2013 , 4, 25-36	57
787	βSynuclein in cutaneous autonomic nerves. 2013 , 81, 1604-10	155
786	βSynuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology. 2014 , 219, 1513-26	42
785	Parkinson-Syndrom(e) - Neue Konzepte ff.eine sich ausbreitende Erkrankung?. 2013 , 40, 327-332	
784	Specific pesticide-dependent increases in βsynuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. 2013 , 133, 289-97	33
783	Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. 2013 , 84, 674-80	74
782	Alpha-synuclein expression patterns in the colonic submucosal plexus of the aging Fischer 344 rat: implications for biopsies in aging and neurodegenerative disorders?. 2013 , 25, e621-33	8
781	Macrophages are unsuccessful in clearing aggregated alpha-synuclein from the gastrointestinal tract of healthy aged Fischer 344 rats. 2013 , 296, 654-69	18
780	Mind the gut: secretion of βSynuclein by enteric neurons. 2013 , 125, 487-90	26

779	Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. 2013 , 18, 187-96	30
778	Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. 2013 , 72, 119-29	83
777	Submandibular gland biopsy for the diagnosis of Parkinson disease. 2013 , 72, 130-6	89
776	Parkinson disease affects peripheral sensory nerves in the pharynx. 2013 , 72, 614-23	88
775	Unimpaired postprandial pancreatic polypeptide secretion in Parkinson's disease and REM sleep behavior disorder. 2013 , 28, 529-33	7
774	Can patient-specific transdifferentiated neuronal cells help us understand the cellular pathology of Parkinson's disease?. 2013 , 8, 605-607	
773	[Cellular pathology of neurodegenerative disorders]. 2013 , 53, 609-17	2
772	Changes of the enteric nervous system in amyloid- β protein precursor transgenic mice correlate with disease progression. 2013 , 36, 7-20	57
771	Astrocytes Role in Parkinson: A Double-Edged Sword. 2013 ,	10
770	Accumulation of Alpha-synuclein Causes Colonic Dysmotility Independently of Enteric Nervous Damage in the Early Stage of Parkinson's Disease (Neurogastroenterol Motil 2012;24:e425-e436). 2013 , 19, 264-6	1
769	Protein Transmission, Seeding and Degradation: Key Steps for β synuclein Prion-Like Propagation. 2014 , 23, 324-36	36
768	Nonmotor symptoms in a malaysian Parkinson's disease population. 2014 , 2014, 472157	14
767	Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. 2014 , 8, 211	221
766	Parkinson's disease and the gut: 'the wheel is come full circle'. 2014 , 4, 577-8	4
765	Biomarkers in biological fluids for dementia with Lewy bodies. 2014 , 6, 72	24
764	Proteomics as a new paradigm to tackle Parkinson's disease research challenges. 2014 , 4-5, 1-17	9
763	Gut feelings about smoking and coffee in Parkinson's disease. 2014 , 29, 976-9	72
762	Alimentary, my dear Watson? The challenges of enteric β synuclein as a Parkinson's disease biomarker. 2014 , 29, 444-50	64

761	The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. 2014 , 6, 46	135
760	Delayed gastric emptying in Parkinson's disease. 2014 , 29, 23-32	96
759	Early and persistent expression of phosphorylated α -synuclein in the enteric nervous system of A53T mutant human α -synuclein transgenic mice. 2014 , 73, 1144-51	29
758	Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. 2014 , 130, 59-72	102
757	Gastrointestinal involvement in Parkinson's disease: the horse or the cart. 2014 , 211, 271-2	1
756	Staged pathology in Parkinson's disease. 2014 , 20 Suppl 1, S57-61	10
755	Dysautonomia in Parkinson disease. 2014 , 4, 805-26	96
754	The pathomechanisms underlying Parkinson's disease. 2014 , 14, 199-215	48
753	Enteric GFAP expression and phosphorylation in Parkinson's disease. 2014 , 130, 805-15	95
752	The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. 2014 , 20, 368-74	72
751	Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease. 2014 , 21, 649-67	47
750	The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. 2014 , 211, 434-46	50
749	Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro. 2014 , 25, 170-82	22
748	Degeneration of nigrostriatal dopaminergic neurons in an experimental model of the early clinical stage of Parkinson's disease. 2014 , 8, 184-192	3
747	Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. 2014 , 50, 2456-62	52
746	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. 2014 , 82, 858-64	96
745	Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. 2014 , 128, 805-20	522
744	Peripheral alpha-synuclein and Parkinson's disease. 2014 , 29, 963-6	27

743	Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. 2014 , 14, 495	85
742	Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. 2014 , 261, 1112-8	76
741	Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. 2014 , 3, 10	28
740	Peptidoglycan recognition protein genes and risk of Parkinson's disease. 2014 , 29, 1171-80	37
739	Pharma-Nutrition. 2014 ,	
738	Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. 2014 , 20, 980-5	79
737	Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. 2014 , 29, 999-1009	144
736	Intramuscular injection of β synuclein induces CNS β synuclein pathology and a rapid-onset motor phenotype in transgenic mice. 2014 , 111, 10732-7	229
735	Imaging of olfactory bulb and gray matter volumes in brain areas associated with olfactory function in patients with Parkinson's disease and multiple system atrophy. 2014 , 83, 564-70	40
734	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. 2014 , 128, 99-109	157
733	Appraisal of the dopaminergic and noradrenergic innervation of the submucosal plexus in PD. 2014 , 4, 571-6	25
732	Sudomotor and cardiovascular dysfunction in patients with early untreated Parkinson's disease. 2014 , 4, 385-93	15
731	The avascular zone and neuronal remodeling of the fovea in Parkinson disease. 2015 , 2, 196-201	25
730	Linking Smoking, Coffee, Urate, and Parkinson's Disease - A Role for Gut Microbiota?. 2015 , 5, 255-62	46
729	Parkinson fñgt im Darm an. 2015 , 16, 22-23	
728	Appendectomy may delay Parkinson's disease Onset. 2015 , 30, 1404-7	35
727	Distribution of β synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. 2015 , 3, 57	41
726	Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease. 2015 , 27, 1783-95	20

725	Diagnosis of Parkinson's disease: progress and future prospects. 2015 , 19	0
724	Brain-gut-microbiota axis in Parkinson's disease. 2015 , 21, 10609-20	305
723	Neurodegenerative changes in the brainstem and olfactory bulb in people older than 50 years old: a descriptive study. 2015 , 73, 569-77	2
722	Role of α and β Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies. 2015 , 5, 1000-11	9
721	Immune aging, dysmetabolism, and inflammation in neurological diseases. 2015 , 9, 172	150
720	Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease. 2015 , 2015, 476041	32
719	The Role of β Synuclein and LRRK2 in Tau Phosphorylation. 2015 , 2015, 734746	11
718	Lower urinary tract dysfunction in patients with parkinsonism and other neurodegenerative disorders. 2015 , 130, 335-56	27
717	Colonic mucosal α -synuclein lacks specificity as a biomarker for Parkinson disease. 2015 , 84, 609-16	110
716	Investigation of tyrosine hydroxylase and BDNF in a low-dose rotenone model of Parkinson's disease. 2015 , 70, 33-41	23
715	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with ^{11}C -donepezil PET. 2015 , 138, 653-63	103
714	Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. 2015 , 21, 199-204	18
713	Spreading of pathology in neurodegenerative diseases: a focus on human studies. 2015 , 16, 109-20	484
712	Role of β Synuclein in inducing innate and adaptive immunity in Parkinson disease. 2015 , 5, 1-19	129
711	The power in numbers: gut microbiota in Parkinson's disease. 2015 , 30, 296-8	19
710	Potential of Cellular and Animal Models Based on a Prion-Like Propagation of β Synuclein for Assessing Antiparkinson Agents. 2015 , 52, 226-35	6
709	Environment-contact administration of rotenone: A new rodent model of Parkinson's disease. 2015 , 294, 149-61	33
708	Peripheral synuclein tissue markers: a step closer to Parkinson's disease diagnosis. 2015 , 138, 2120-2	14

707	Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients. 2015 , 30, 404-17	26
706	Parkinson's Disease. 2015 , 267-288	
705	Structural alterations of the intestinal epithelial barrier in Parkinson's disease. 2015 , 3, 12	136
704	Gastrointestinal dysfunction in Parkinson's disease. 2015 , 14, 625-39	436
703	Neuropathobiology of non-motor symptoms in Parkinson disease. 2015 , 122, 1429-40	105
702	Activation of MyD88-dependent TLR1/2 signaling by misfolded α -synuclein, a protein linked to neurodegenerative disorders. 2015 , 8, 1-45	151
701	Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. 2015 , 21, 455-60	39
700	Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. 2015 , 23, 488-500	28
699	The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. 2015 , 16, 2449-64	38
698	Complex liaisons moving forward the Parkinson's disease? An appraisal. 2015 , 5, 77-87	1
697	Bent out of shape: α -Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. 2015 , 589, 3749-59	41
696	Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. 2015 , 11, 625-36	335
695	Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal. 2015 , 262, 1946-53	9
694	Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease. 2015 , 15, 78	15
693	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. 2015 , 21, 1407-14	43
692	Enteric nervous system α -Synuclein immunoreactivity in idiopathic REM sleep behavior disorder. 2015 , 85, 1761-8	94
691	Ursache der Parkinson-Krankheit: Braak revisited. 2015 , 41, 573-578	
690	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. <i>Neuroscience Letters</i> , 2015 , 602, 145-9	3-3 34

689	[Is Parkinson's disease a prion disease?]. 2015 , 171, 812-24	5
688	From Man to Mouse. 2015 , 287-306	2
687	The Phenotypic Spectrum of Parkinson Disease. 2015 , 229-241	
686	An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. 2015 , 46, 101-16	183
685	Gut microbiota are related to Parkinson's disease and clinical phenotype. 2015 , 30, 350-8	973
684	Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. 2015 , 21, 120-5	35
683	In vivo gastric detection of β synuclein inclusions in Parkinson's disease. 2015 , 30, 517-24	82
682	Enteric glial cells: new players in Parkinson's disease?. 2015 , 30, 494-8	72
681	Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies. 2016 , 4,	3
680	Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments. 2016 , 2016, 6762528	57
679	More than a Rumor Spreads in Parkinson's Disease. 2016 , 10, 608	9
678	Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. 2016 , 10, 408	198
677	Dietary Plant Lectins Appear to Be Transported from the Gut to Gain Access to and Alter Dopaminergic Neurons of <i>Caenorhabditis elegans</i> , a Potential Etiology of Parkinson's Disease. 2016 , 3, 7	9
676	Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker. 2016 , 31, 241-9	54
675	Pathological β synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. 2016 , 79, 940-9	194
674	Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature. 2016 , 23, 247-61	65
673	What a gastrointestinal biopsy can tell us about Parkinson's disease?. 2016 , 28, 966-74	20
672	FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. 2016 , 291, 20811-21	51

671	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. 2016 , 6, 153-63	39
670	Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. 2016 , 6, 761-770	50
669	Neuroinvasion of β Synuclein Prionoids after Intraperitoneal and Intraglossal Inoculation. 2016 , 90, 9182-93	63
668	Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle. 2016 , 29, 773-780	42
667	The nonmotor features of Parkinson's disease: pathophysiology and management advances. 2016 , 29, 467-73	36
666	Gastrointestinal Dysfunction and Neuropathologic Correlations in Parkinson Disease. 2016 , 50, e85-90	14
665	How strong is the evidence that Parkinson's disease is a prion disorder?. 2016 , 29, 459-66	48
664	Virtual reality systems in the rehabilitation of Parkinson's disease. 2016 ,	5
663	Alpha-Synuclein as a Diagnostic Biomarker for Parkinson's Disease. 2016 , 215-234	1
662	Vagal neurocircuitry and its influence on gastric motility. 2016 , 13, 389-401	135
661	Imaging Systemic Dysfunction in Parkinson's Disease. 2016 , 16, 51	16
660	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. 2016 , 28, 1781-1791	31
659	Epidemiology of Parkinson Disease. 2016 , 34, 955-965	159
658	Prodromal symptoms of Parkinson's disease: Implications for epidemiological studies of disease etiology. 2016 , 172, 503-511	13
657	Gut Feelings About β Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?. 2016 , 31, 193-202	50
656	The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. 2016 , 137, 331-59	124
655	Review: The spectrum of clinical features seen with alpha synuclein pathology. 2016 , 42, 6-19	56
654	Review: Sporadic Parkinson's disease: development and distribution of β Synuclein pathology. 2016 , 42, 33-50	232

653	Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. 2016 , 32, 66-72	532
652	Alteration of colonic excitatory tachykinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. 2016 , 13, 146	50
651	199 years of Parkinson disease - what have we learned and what is the path to the future?. 2016 , 139 Suppl 1, 3-7	15
650	Potential Pathways of Abnormal Tau and β Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. 2016 , 8,	77
649	Inflammation: the Common Link in Brain Pathologies. 2016 ,	1
648	Neuroinflammation During Parkinson's Disease: Key Cells and Molecules Involved in It. 2016 , 185-208	2
647	[Problem solving care models for Parkinson's disease]. 2016 , 157, 855-68	2
646	Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion. 2016 , 123, 1395-1398	6
645	Cross-linking for the analysis of β Synuclein in the enteric nervous system. 2016 , 139, 839-847	18
644	Restoration of intestinal function in an MPTP model of Parkinson's Disease. 2016 , 6, 30269	20
643	Enteric neurons from Parkinson's disease patients display ex vivo aberrations in mitochondrial structure. 2016 , 6, 33117	15
642	Neurovascular Interface in Porcine Small Intestine: Specific for Nitroergic rather than Nonnitroergic Neurons. 2016 , 201, 203-10	2
641	High-resolution Anorectal Manometry in Parkinson Disease With Defecation Disorder: A Comparison With Functional Defecation Disorder. 2016 , 50, 566-71	7
640	Changes in the sympathetic innervation of the gut in rotenone treated mice as possible early biomarker for Parkinson's disease. 2016 , 26, 211-22	14
639	Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. 2016 , 4, 35	53
638	Association Between Parkinson's Disease and Inflammatory Bowel Disease: a Nationwide Taiwanese Retrospective Cohort Study. 2016 , 22, 1049-55	100
637	Alpha-Synuclein as a Biomarker for Parkinson's Disease. 2016 , 26, 410-8	128
636	RETRACTED ARTICLE: A variety of pesticides trigger in vitro β Synuclein accumulation, a key event in Parkinson's disease. 2016 , 90, 1279-1279	9

635	Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. 2016 , 27, 1-8	112
634	βSynuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. 2016 , 36, 437-48	46
633	Low Serum Vitamin D Levels May Contribute to Gastric Dysmotility in de novo Parkinson's Disease. 2016 , 16, 199-205	14
632	Involvement of catecholaminergic neurons in motor innervation of striated muscle in the mouse esophagus. 2016 , 145, 573-85	2
631	The effect of subthalamic deep brain stimulation on gastric motility in Parkinson's disease. 2016 , 26, 35-40	22
630	Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. 2016 , 356, 434-44	36
629	Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. 2016 , 23, 1-9	199
628	Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. 2016 , 158, 52-62	265
627	Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. 2016 , 22, 22-32	32
626	Constipation preceding Parkinson's disease: a systematic review and meta-analysis. 2016 , 87, 710-6	96
625	Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society- Unified Parkinson's Disease Rating Scale. 2017 , 4, 68-77	20
624	Esophageal dysfunction in different stages of Parkinson's disease. 2017 , 29, e12915	39
623	The Search for a Peripheral Biopsy Indicator of βSynuclein Pathology for Parkinson Disease. 2017 , 76, 2-15	50
622	Parkinson's disease as a multisystem disorder. 2017 , 124, 709-713	28
621	Biochemical analysis of βSynuclein extracted from control and Parkinson's disease colonic biopsies. <i>Neuroscience Letters</i> , 2017 , 641, 81-86	3-3 15
620	Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells. 2017 , 43, 584-603	57
619	A practical review of gastrointestinal manifestations in Parkinson's disease. 2017 , 39, 17-26	26
618	Gut microbiota: Implications in Parkinson's disease. 2017 , 38, 1-7	125

617	Immunochemical Detection of β Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. 2017 , 8, 1170-1176	32
616	Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. 2017 , 133, 535-545	135
615	The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. 2017 , 11, 359-368	33
614	The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?. 2017 , 3, 3	252
613	Donepezil for Constipation in Lewy Body Diseases: Four Case Studies. 2017 , 59, 19-27	4
612	Exosomes in Toxicology: Relevance to Chemical Exposure and Pathogenesis of Environmentally Linked Diseases. 2017 , 158, 3-13	31
611	Aszensionshypothese beim idiopathischen Parkinson-Syndrom. 2017 , 44, 170-179	
610	[Nonmotor symptoms in Parkinson's disease]. 2017 , 88, 874-887	6
609	Imaging Parkinson's disease below the neck. 2017 , 3, 15	9
608	Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. 2017 , 9, 39	274
607	Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. 2017 , 88, 1996-2002	219
606	Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. 2017 , 5, 1	56
605	RNA-Seq Expression Analysis of Enteric Neuron Cells with Rotenone Treatment and Prediction of Regulated Pathways. 2017 , 42, 572-582	3
604	Association between Parkinson's disease and risk of colorectal cancer. 2017 , 35, 42-47	12
603	Management of Autonomic Dysfunction in Parkinson's Disease. 2017 , 37, 176-185	14
602	Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies. 2017 , 12, 44	33
601	Bedside Approach to Autonomic Disorders. 2017 ,	1
600	An update on the recognition and treatment of autonomic symptoms in Parkinson's disease. 2017 , 17, 791-799	5

599	Brain Autoimmunity and Intestinal Microbiota: 100 Trillion Game Changers. 2017 , 38, 483-497	59
598	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. 2017 , 123, 22-33	13
597	The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies. 2017 , 817, 86-95	110
596	Neurotransmission systems in Parkinson's disease. 2017 , 28, 509-536	33
595	Autonomic Symptoms in Dementia with Lewy Bodies. 2017 , 111-128	2
594	Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. 2017 , 7, S71-S85	175
593	Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α -Synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum. 2017 , 29, e12985	11
592	Brain-to-stomach transfer of α -Synuclein via vagal preganglionic projections. 2017 , 133, 381-393	118
591	New olfactometric findings in Parkinson's disease. 2017 , 42, 837-843	11
590	Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model. 2017 , 56, 775-788	148
589	Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinson's Disease. 2017 , 33, 483-492	16
588	Prions. 2017 ,	2
587	The Gut and Nonmotor Symptoms in Parkinson's Disease. 2017 , 134, 787-809	29
586	Constipation in Parkinson's Disease. 2017 , 134, 811-826	38
585	Autonomic Dysfunction in Parkinson's Disease: Cardiovascular Symptoms, Thermoregulation, and Urogenital Symptoms. 2017 , 134, 771-785	16
584	Fundamental limit of alpha-synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson's disease: Comparison with surgical specimens. 2017 , 44, 73-78	18
583	Microbiota and neurodegenerative diseases. 2017 , 30, 630-638	43
582	Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms. 2017 , 48, 221-227	17

581	More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota. 2017 , 24, 1375-1383	74
580	Vaccination strategies in tauopathies and synucleinopathies. 2017 , 143, 467-488	22
579	Preparation and Immunostaining of the Myenteric Plexus of Prion-Infected Mice. 2017 , 1658, 285-292	0
578	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. 2017 , 124, 1029-1036	10
577	Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to β synuclein targeted disease modification. 2017 , 298, 172-179	33
576	Premotor Diagnosis of Parkinson's Disease. 2017 , 33, 526-534	31
575	Non-CNS pathogenic origin of Parkinson's disease. 2017 , 264, 2027-2030	7
574	Exploring the microbiome in health and disease: Implications for toxicology. 2017 , 1, 239784731774188	19
573	Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson's Disease. 2017 , 4, 361-368	33
572	The Biology and Pathobiology of β Synuclein. 2017 , 109-130	1
571	Hypothesis of Ascension in Idiopathic Parkinson's Disease. 2017 , 01, E28-E35	
570	Colonic diverticular disease: A new risk factor for Parkinson's disease?. 2017 , 42, 61-65	2
569	A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity. 2017 , 9, 456-463	149
568	Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview. 2017 , 15, 55-92	2
567	Neuropathology of Nonmotor Symptoms of Parkinson's Disease. 2017 , 133, 13-62	26
566	Self-administration of methamphetamine alters gut biomarkers of toxicity. 2017 , 46, 1918-1932	8
565	The microbiome: current and future view of an ancient paradigm. 2017 , 12, 831-834	1
564	β Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects. 2017 , 38, 171-179	11

563	Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of β Synuclein Fibrils. 2017 , 91,	57
562	Host-microbiome interactions: the aryl hydrocarbon receptor and the central nervous system. 2017 , 95, 29-39	28
561	Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures. 2017 , 197, 46-51	24
560	Clinical Assessment of the Autonomic Nervous System. 2017 ,	4
559	Proteolysis of β Synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. 2017 , 140, 662-678	41
558	Dementia with Lewy Bodies. 2017 ,	1
557	Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated β Synuclein in the Enteric Nervous System of A53T Mutant Human β Synuclein Transgenic Mice. 2017 , 76, 1046-1057	28
556	Neuropathology of dementia. 94-122	1
555	Vertebrate food products as a potential source of prion-like β Synuclein. 2017 , 3, 33	17
554	Colonic Oxidative and Mitochondrial Function in Parkinson's Disease and Idiopathic REM Sleep Behavior Disorder. 2017 , 2017, 9816095	3
553	Exploring Braak's Hypothesis of Parkinson's Disease. 2017 , 8, 37	131
552	Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. 2017 , 11, 3	31
551	Live calcium and mitochondrial imaging in the enteric nervous system of Parkinson patients and controls. 2017 , 6,	12
550	Transmission of β Synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?. 2017 , 5, 71	118
549	β Synuclein in gut endocrine cells and its implications for Parkinson's disease. 2017 , 2,	94
548	Structure, Distribution, and Genetic Profile of β Synuclein and Their Potential Clinical Application in Parkinson's Disease. 2017 , 10, 69-79	17
547	Autonomic dysfunction in genetic forms of synucleinopathies. 2018 , 33, 359-371	12
546	Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. 2018 , 70, 194-202	173

545	Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease. 2018 , 44, 722-736	27
544	The Microbiome in Neurodegenerative Disease. 2018 , 7, 81-91	5
543	Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries. 2018 , 50, 23-28	40
542	Parkinson's disease from the gut. 2018 , 1693, 201-206	80
541	Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models. 2018 , 55, 7297-7316	56
540	Neurodegenerative Chemosensory Disorders. 293-386	
539	Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. 2018 , 112, 106-118	86
538	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. 2018 , 125, 591-613	13
537	Enteric nervous system manifestations of neurodegenerative disease. 2018 , 1693, 207-213	55
536	Constipation in Parkinson's Disease: a Nuisance or Nuanced Answer to the Pathophysiological Puzzle?. 2018 , 20, 1	13
535	Alpha-synuclein is present in dental calculus but not altered in Parkinson's disease patients in comparison to controls. 2018 , 265, 1334-1337	0
534	Les synuclnopathies sont-elles des maladies ^ prions?. 2018 , 9, 145-151	
533	Extracellular β synuclein Disrupts Membrane Nanostructure and Promotes S-Nitrosylation-Induced Neuronal Cell Death. 2018 , 19, 1118-1129	11
532	Parkinson's Disease: Contemporary Concepts and Clinical Management. 2018 , 349-378	
531	Characterization and transplantation of enteric neural crest cells from human induced pluripotent stem cells. 2018 , 23, 499-508	39
530	β synuclein nonhuman primate models of Parkinson's disease. 2018 , 125, 385-400	18
529	Gut-brain and brain-gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet. 2018 , 21, 391-402	49
528	Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. 2018 , 109, 219-225	54

527	Disruptive physiology: olfaction and the microbiome-gut-brain axis. 2018 , 93, 390-403	21
526	Intercellular transfer of pathogenic β synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. 2018 , 61, 52-65	42
525	Does Parkinson's disease start in the gut?. 2018 , 135, 1-12	125
524	The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. 2018 , 33, 88-98	245
523	Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. 2018 , 33, 41-50	74
522	Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. 2018 , 162, 17-36	27
521	Nano- and neurotoxicology: An emerging discipline. 2018 , 160, 45-63	46
520	Age-dependent elevations of oligomeric and phosphorylated alpha-synuclein synchronously occurs in the brain and gastrointestinal tract of cynomolgus monkeys. <i>Neuroscience Letters</i> , 2018 , 662, 276-282 ³⁻³	9
519	Donepezil for Constipation in Lewy Body Disease: A Twelve-Month Follow-Up. 2018 , 12,	3
518	Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. 2018 , 25, 3930-3952	91
517	The Impact of Ghrelin on the Survival and Efficacy of Dopaminergic Fetal Grafts in the 6-OHDA-Lesioned Rat. 2018 , 395, 13-21	4
516	The imbalance of serotonergic circuitry impairing the crop supercontractile muscle activity and the mitochondrial morphology of PD PINK1 <i>Drosophila melanogaster</i> are rescued by <i>Mucuna pruriens</i> . 2018 , 111, 32-40	5
515	What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?. 2018 , 19,	20
514	Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy. 2018 , 19,	16
513	Production of the Neurotoxin Salsolinol by a Gut-Associated Bacterium and Its Modulation by Alcohol. 2018 , 9, 3092	10
512	Secretion and Uptake of β Synuclein Via Extracellular Vesicles in Cultured Cells. 2018 , 38, 1539-1550	42
511	Monoamines in the enteric nervous system. 2018 , 150, 703-709	14
510	Imaging the Autonomic Nervous System in Parkinson's Disease. 2018 , 18, 79	11

509	Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. 2018 , 21, 1341-1349	178
508	Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects. 2018 , 16, 489-510	9
507	Clinical characteristics and quality of life in Chinese patients with multiple system atrophy. 2018 , 8, e01135	3
506	Gastrointestinal Dysfunction in Parkinson's Disease. 2018 , 20, 54	52
505	Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. 2018 , 43, 1986-1999	68
504	The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?. 2018 , 9, 2047	23
503	Immunosuppressants and risk of Parkinson disease. 2018 , 5, 870-875	39
502	Trockenes Auge unterschätzt und unterdiagnostiziert. 2018 , 29, 24-29	
501	Gangliosides, α Synuclein, and Parkinson's Disease. 2018 , 156, 435-454	37
500	Relation of Enteric α Synuclein to Gastrointestinal Dysfunction in Patients With Parkinson's Disease and in Neurologically Intact Subjects. 2018 , 24, 469-478	19
499	Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review. 2018 , 24, 30-42	82
498	Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. 2018 , 2018, 4784268	202
497	Gangliosides of the Nervous System. 2018 , 1804, 19-55	28
496	Neural Secretions and Regulation of Gut Functions. 2018 , 527-684	
495	Inoculation of α Synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. 2018 , 13, 21	127
494	Models of Network Spread and Network Degeneration in Brain Disorders. 2018 , 3, 788-797	21
493	Parkinson's disease: what the model systems have taught us so far. 2018 , 97, 729-751	8
492	Non-Motor Symptoms of Parkinson's Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients. 2018 , 9, 170	41

491	Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson's disease. 2018 , 7, 13	23
490	Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease. 2018 , 19,	142
489	Testing the Protein Propagation Hypothesis of Parkinson Disease. 2018 , 12, 1179069518786715	13
488	Parkinson's disease pathogenesis, evolution and alternative pathways: A review. 2018 , 174, 699-704	16
487	Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). 2018 , 77, 793-802	22
486	Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type β synuclein. 2018 , 117, 170-180	13
485	Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD?. 2018 , 373, 267-286	22
484	Excess amounts of 3-iodo-l-tyrosine induce Parkinson-like features in experimental approaches of Parkinsonism. 2018 , 67, 178-189	5
483	Prion-like propagation of β synuclein in the gut-brain axis. 2018 , 140, 341-346	7
482	The enteric nervous system in PD: gateway, bystander victim, or source of solutions. 2018 , 373, 313-326	10
481	Gut Microbiota in Brain Development and Disorders of the CNS: Therapeutic Strategies Involving Dietary Modification, Pro- and Prebiotic Intervention, and Fecal Microbiota Transplantation (FMT) Therapy. 2018 , 517-594	
480	Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases. 2019 , 56, 2256-2277	25
479	Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human β synuclein Over-Expressing Mouse Model. 2019 , 13, 839	64
478	Gastric dysmotility in Parkinson's disease is not caused by alterations of the gastric pacemaker cells. 2019 , 5, 15	12
477	Atrophic Myenteric and Submucosal Neurons Are Observed in Parkinson's Disease. 2019 , 2019, 7935820	10
476	Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts. 2019 , 14, 969-982	3
475	Neonatal Brain Injury and Genetic Causes of Adult-Onset Neurodegenerative Disease in Mice Interact With Effects on Acute and Late Outcomes. 2019 , 10, 635	3
474	Parkinson's Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation. 2019 , 25, 363-376	66

473	Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson's disease: a meta-analysis. 2019 , 52, e8443	12
472	The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function. 2019 , 14, e0218252	31
471	Neuronal microtubules and proteins linked to Parkinson's disease: a relevant interaction?. 2019 , 400, 1099-1112	9
470	The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review. 2019 , 11, 130	39
469	Inflammatory Bowel Diseases and Parkinson's Disease. 2019 , 9, S331-S344	40
468	Image Segmentation and Feature Analyses of Imitated Intense X-ray Spot Radiation Source. 2019 ,	
467	The microbiome of the upper respiratory tract in health and disease. 2019 , 17, 87	118
466	The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease. 2019 , 10, 1155	54
465	The Microbiota-Gut-Brain Axis. 2019 , 99, 1877-2013	979
464	Probiotics for Parkinson's Disease. 2019 , 20,	56
463	Excessive daytime sleepiness and topographic expansion of Lewy pathology. 2019 , 93, e1425-e1432	9
462	Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. 2019 , 12, 67-83	36
461	Nonpharmacological Modulation of Chronic Inflammation in Parkinson's Disease: Role of Diet Interventions. 2019 , 2019, 7535472	6
460	Gut Inflammation in Association With Pathogenesis of Parkinson's Disease. 2019 , 12, 218	35
459	The Intestinal Barrier in Parkinson's Disease: Current State of Knowledge. 2019 , 9, S323-S329	27
458	The prion-like spreading of β synuclein: From in vitro to in vivo models of Parkinson's disease. 2019 , 50, 89-101	38
457	The effects of rotenone on TH, BDNF and BDNF-related proteins in the brain and periphery: Relevance to early Parkinson's disease. 2019 , 97, 23-32	5
456	Dementia with Lewy bodies: an update and outlook. 2019 , 14, 5	100

455	T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease. 2019 , 10, 239		57
454	Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease. 2019 , 10, 812-823		20
453	βSynuclein 2.0 - Moving towards Cell Type Specific Pathophysiology. 2019 , 412, 248-256		6
452	Cancer risk in patients with Parkinson's disease in South Korea: A nationwide, population-based cohort study. 2019 , 117, 5-13		20
451	βSynuclein pathology in Parkinson's disease and related βSynucleinopathies. <i>Neuroscience Letters</i> , 2019 , 709, 134316	3-3	85
450	A secret that underlies Parkinson's disease: The damaging cycle. 2019 , 129, 104484		11
449	Prospective cohort study of patients with early gastric cancer to detect prodromal Parkinson disease (EGC-PPD): A study protocol and baseline characteristics. 2019 , 66, 26-32		1
448	Spreading of alpha-synuclein - relevant or epiphenomenon?. 2019 , 150, 605-611		17
447	Erectile Dysfunction Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study in Olmsted County. 2019 , 2019, 6303945		4
446	Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates. 2019 , 12, 113-126		21
445	Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification. 2019 , 129, 38-43		35
444	Do your gut microbes affect your brain dopamine?. 2019 , 236, 1611-1622		39
443	Quantitative MRI evaluation of gastric motility in patients with Parkinson's disease: Correlation of dyspeptic symptoms with volumetry and motility indices. 2019 , 14, e0216396		10
442	Autoimmunity in Parkinson's Disease: The Role of βSynuclein-Specific T Cells. 2019 , 10, 303		76
441	Effect of naturally occurring βSynuclein-antibodies on toxic βSynuclein-fragments. <i>Neuroscience Letters</i> , 2019 , 704, 181-188	3-3	5
440	Parkinson's disease: Mechanisms, translational models and management strategies. 2019 , 226, 77-90		147
439	Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies. 2019 , 15, 135-142		21
438	βSynuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. 2019 , 138, 1-21		60

437	Local Gastrointestinal Injury Exacerbates Inflammation and Dopaminergic Cell Death in Parkinsonian Mice. 2019 , 35, 918-930	8
436	Diagnostic utility of gut β -synuclein in Parkinson's disease: A systematic review and meta-analysis. 2019 , 364, 340-347	18
435	Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites. 2019 , 16, 741-760	60
434	Reducing the Amyloidogenicity of Functional Amyloid Protein FapC Increases Its Ability To Inhibit β -Synuclein Fibrillation. 2019 , 4, 4029-4039	17
433	Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology. 2019 ,	
432	The gut-brain axis in the pathogenesis of Parkinson's disease. 2019 , 5, 73-81	7
431	Evaluation of Gut Microbiota in Parkinson's Disease using Gas Chromatography with Mass Spectrometric Detection. 2019 , 45, 855-862	1
430	Physical activity and prodromal features of Parkinson disease. 2019 , 93, e2157-e2169	12
429	Multiple system atrophy. 2019 , 149, 137-192	35
428	Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. 2019 , 16, 250	36
427	Fecal microbiota transplantation to treat Parkinson's disease with constipation: A case report. 2019 , 98, e16163	68
426	Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. <i>Neuroscience Letters</i> , 2019 , 696, 132-139	3-3 14
425	The appendix and the risk of Parkinson's disease: Appended notes on correlation and causation. 2019 , 34, 199	1
424	Age-related diseases as vicious cycles. 2019 , 49, 11-26	33
423	Can the gut be the missing piece in uncovering PD pathogenesis?. 2019 , 59, 26-31	31
422	Association of SNCA variants with β -synuclein of gastric and colonic mucosa in Parkinson's disease. 2019 , 61, 151-155	6
421	The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration. 2019 , 34, 167-179	36
420	Gut microbiota in neurodegenerative disorders. 2019 , 328, 98-104	115

419	Unexpected Roles for the Second Brain: Enteric Nervous System as Master Regulator of Bowel Function. 2019 , 81, 235-259	57
418	Invited Review: From nose to gut - the role of the microbiome in neurological disease. 2019 , 45, 195-215	40
417	Enteric Pathologic Manifestations of Alpha-Synucleinopathies. 2019 , 27, 543-548	8
416	Parkinson's disease and the gastrointestinal microbiome. 2020 , 267, 2507-2523	59
415	Pricing Vulnerable Options with Stochastic Volatility and Stochastic Interest Rate. 2020 , 56, 391-429	9
414	Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease. 2020 , 32, e12782	4
413	Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. 2020 , 47, 1984-1997	4
412	Microbiota-Gut-Brain Axis: New Therapeutic Opportunities. 2020 , 60, 477-502	112
411	Nigral overexpression of β -synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome. 2020 , 32, e13726	36
410	Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. 2020 , 40, 30-39	21
409	La maladie de Parkinson est aussi une maladie du tube digestif. 2020 , 204, 66-71	
408	The gut in Parkinson's disease: Bottom-up, top-down, or neither?. 2020 , 32, e13777	24
407	The gut microbiome in neurological disorders. 2020 , 19, 179-194	265
406	Antibiotic exposure and risk of Parkinson's disease in Finland: A nationwide case-control study. 2020 , 35, 431-442	25
405	Innate and adaptive immune responses in Parkinson's disease. 2020 , 252, 169-216	29
404	Sodium butyrate causes β -synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. 2020 , 387, 111772	23
403	Initiation of Parkinson's disease from gut to brain by β -secretase. 2020 , 30, 70-87	23
402	The catecholaldehyde hypothesis: where MAO fits in. 2020 , 127, 169-177	21

401	Alpha-synuclein oligomerization and dopaminergic degeneration occur synchronously in the brain and colon of MPTP-intoxicated parkinsonian monkeys. <i>Neuroscience Letters</i> , 2020 , 716, 134640	3-3	7
400	Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice. 2020 , 134, 104696		18
399	Limited spread of pathology within the brainstem of β synuclein BAC transgenic mice inoculated with preformed fibrils into the gastrointestinal tract. <i>Neuroscience Letters</i> , 2020 , 716, 134651	3-3	20
398	Detection of Phosphorylated Alpha-Synuclein in the Muscularis Propria of the Gastrointestinal Tract Is a Sensitive Predictor for Parkinson's Disease. 2020 , 2020, 4687530		4
397	Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology. 2020 , 8, 573696		24
396	No enhanced (p-) β synuclein deposition in gastrointestinal tissue of Parkinson's disease patients. 2020 , 80, 82-88		6
395	From Synaptic Protein to Prion: The Long and Controversial Journey of β synuclein. 2020 , 12, 584536		12
394	The Role of β synuclein Oligomers in Parkinson's Disease. 2020 , 21,		31
393	Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease. 2020 , 21,		2
392	Preferential microglial activation associated with pathological alpha synuclein transmission. 2020 , 81, 469-476		6
391	Microorganisms that are related with increased risk for Parkinson's disease. 2020 ,		1
390	Novel antibodies detect additional β synuclein pathology in synucleinopathies: potential development for immunotherapy. 2020 , 12, 159		11
389	Systems Biology Approaches to Understand the Host-Microbiome Interactions in Neurodegenerative Diseases. 2020 , 14, 716		20
388	Where and how alpha-synuclein pathology spreads in Parkinson's disease. 2020 , 40, 415-425		16
387	β synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?. 2021 , 27, 367-387		3
386	In vivo distribution of β synuclein in multiple tissues and biofluids in Parkinson disease. 2020 , 95, e1267-e1284		37
385	The Microbiome as a Modifier of Neurodegenerative Disease Risk. 2020 , 28, 201-222		35
384	Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease. 2020 , 10, 570658		14

- 383 Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics. **2020**, 25, 2515690X20957225 20
- 382 From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease. **2020**, 11, 557928 5
- 381 The Role of Electrochemical Skin Conductance as a Screening Test of Cardiovascular Autonomic Neuropathy in Patients with Parkinson's Disease. **2020**, 17, 3
- 380 Parkinson's disease: Are gut microbes involved?. **2020**, 319, G529-G540 4
- 379 Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease. **2020**, 10, 1477-1491 10
- 378 The role of natural killer cells in Parkinson's disease. **2020**, 52, 1517-1525 13
- 377 Fatal autonomic failure due to premanifesting Parkinson's disease only diagnosed at autopsy. **2020**, 8, 1997-1999
- 376 Gut-Brain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease. **2020**, 11, 849 5
- 375 Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease. **2020**, 143, 2474-2489 19
- 374 The Rotenone Models Reproducing Central and Peripheral Features of Parkinson's Disease. **2020**, 1, 1-14 4
- 373 Norepinephrine depleting toxin DSP-4 and LPS alter gut microbiota and induce neurotoxicity in α -Synuclein mutant mice. **2020**, 10, 15054 2
- 372 Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease. **2020**, 5, 46
- 371 In Search of Effective Treatments Targeting α -Synuclein Toxicity in Synucleinopathies: Pros and Cons. **2020**, 8, 559791 9
- 370 Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease. **2020**, 12, 603849 7
- 369 Fisetin Regulates Gut Microbiota and Exerts Neuroprotective Effect on Mouse Model of Parkinson's Disease. **2020**, 14, 549037 10
- 368 Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder. **2020**, 5, 14
- 367 Neuron-Astrocyte Interactions in Parkinson's Disease. **2020**, 9, 20
- 366 Korean Red Ginseng Regulates Intestinal Tight Junction and Inflammation in the Colon of a Parkinson's Disease Mouse Model. **2020**, 23, 1231-1237 7

365	Cell-to-Cell Transmission of Tau and β Synuclein. 2020 , 26, 936-952	39
364	A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease. 2020 , 19, 97	11
363	Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis. 2020 , 8, 63	22
362	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. 2020 , 143, 1462-1475	60
361	Infections or Sepsis Preceding Clinically Diagnosed β Synucleinopathies: A Case-Control Study. 2020 , 35, 1684-1689	3
360	Increased CSF NFL in Non-demented Parkinson's Disease Subjects Reflects Early White Matter Damage. 2020 , 12, 128	4
359	Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. 2020 , 76, 63-71	13
358	Insulin resistance and Parkinson's disease. 2020 , 293-347	
357	Insulin resistance, dementia, and depression. 2020 , 349-384	
356	Clostridium difficile infection and risk of Parkinson's disease: a Swedish population-based cohort study. 2020 , 27, 2134-2141	5
355	Meta-Analysis of Gut Dysbiosis in Parkinson's Disease. 2020 , 35, 1626-1635	92
354	Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit. 2020 , 11, 364	4
353	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. 2020 , 139, 1001-1024	27
352	Animal Model for Prodromal Parkinson's Disease. 2020 , 21,	5
351	Cerebral dopamine neurotrophic factor is essential for enteric neuronal development, maintenance, and regulation of gastrointestinal transit. 2020 , 528, 2420-2444	8
350	Targeting Gut Microbiota Dysbiosis: Potential Intervention Strategies for Neurological Disorders. 2020 , 6, 415-423	16
349	Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside. 2020 , 329, 113284	23
348	Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease. 2020 , 12, 12	3

347	Microbial BMAA and the Pathway for Parkinson's Disease Neurodegeneration. 2020 , 12, 26	20
346	Glia-Derived Extracellular Vesicles in Parkinson's Disease. 2020 , 9,	14
345	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between Synucleinopathies. 2020 , 267, 3444-3456	10
344	Parkinson's Disease and the Gut: Future Perspectives for Early Diagnosis. 2020 , 14, 626	8
343	Intra-gastrointestinal amyloid- β -42 oligomers perturb enteric function and induce Alzheimer's disease pathology. 2020 , 598, 4209-4223	29
342	Common neurodegenerative disorders in the perioperative setting: Recommendations for screening from the Society for Perioperative Assessment and Quality Improvement (SPAQI). 2020 , 20,	3
341	Treatment of Nonmotor Symptoms Associated with Parkinson Disease. 2020 , 38, 269-292	14
340	Implications of the Gut Microbiome in Parkinson's Disease. 2020 , 35, 921-933	48
339	Organ-On-A-Chip Models of the Brain and the Blood-Brain Barrier and Their Value to Study the Microbiota-Gut-Brain Axis in Neurodegeneration. 2019 , 7, 435	40
338	Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease. 2019 , 10, 1388	35
337	The enteric nervous system: A little brain in the gut 2020 , 26, 31-42	2
336	Assessments of plasma acyl-ghrelin levels in Parkinson's disease patients treated with deep brain stimulation. 2020 , 128, 170299	2
335	Noncanonical Roles of h-syn (A53T) in the Pathogenesis of Parkinson's Disease: Synaptic Pathology and Neuronal Aging. 2020 , 2020, 6283754	2
334	The Mitochondrial Ribosome: A World of Opportunities for Mitochondrial Dysfunction Toward Parkinson's Disease. 2021 , 34, 694-711	1
333	Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. 2021 , 141, 25-37	17
332	Preliminary Findings on Proline-Rich Protein 14 as a Diagnostic Biomarker for Parkinson's Disease. 2021 , 23, 285-291	0
331	Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more 2021 , 177, 260-271	6
330	BDNF and Netrin-1 repression by C/EBP β in the gut triggers Parkinson's disease pathologies, associated with constipation and motor dysfunctions. 2021 , 198, 101905	8

329	Gastrointestinal dysfunction in the synucleinopathies. 2021 , 31, 77-99	7
328	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. 2021 , 177, 175-202	6
327	Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. 2021 , 11, 71-92	7
326	Dopamine and Gastrointestinal Motility. 2021 , 133-202	0
325	The contribution of gut microbiota in the pathogenesis of Parkinson's disease. 2021 , 123-141	
324	Enteric Neurotoxicity and Salsolinol. 2021 , 1-27	
323	Nasopharyngeal Microbiome. 2021 ,	
322	Assessing autonomic dysfunction with functional imaging in Parkinson's disease. 2021 , 91-118	
321	Dysregulation of epithelial ion transport and neurochemical changes in the colon of a parkinsonian primate. 2021 , 7, 9	2
320	Potential roles of functional bacterial amyloid proteins, bacterial biosurfactants and other putative gut microbiota products in the etiopathogeny of Parkinson's Disease. 2021 , 45, 1-16	4
319	Seeding Propensity and Characteristics of Pathogenic α -Syn Assemblies in Formalin-Fixed Human Tissue from the Enteric Nervous System, Olfactory Bulb, and Brainstem in Cases Staged for Parkinson's Disease. 2021 , 10,	5
318	The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. 2021 , 53, 611-625	7
317	Inflammatory Mechanisms in Parkinson's Disease: From Pathogenesis to Targeted Therapies. 2021 , 1073858421992265	
316	Gut microbiota and motoric-cognitive frailty in hospitalized older persons. 2021 , 24, 209-215	
315	Cellular and molecular pathophysiology in the progression of Parkinson's disease. 2021 , 36, 815-827	7
314	Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?. 2020 , 14, 580311	7
313	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. 2021 , 10,	20
312	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences. 2021 , 10,	11

311	NANOTECHNOLOGY-MEDIATED THERAPEUTIC STRATEGIES AGAINST SYNUCLEINOPATHIES IN NEURODEGENERATIVE DISEASE.. 2021 , 31, 100673-100673	0
310	Donepezil and β -Synuclein Constipation: A 48 Month Follow-Up. 2021 , 1-7	0
309	Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease. 2021 , 34, 108807	13
308	Gut Microbiota Interaction with the Central Nervous System throughout Life. 2021 , 10,	15
307	Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug?. 2021 , 36, 829-847	1
306	Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review. 2021 , 13,	1
305	Pathophysiological Changes in the Enteric Nervous System of Rotenone-Exposed Mice as Early Radiological Markers for Parkinson's Disease. 2021 , 12, 642604	2
304	Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics. 2021 , 203, 2895-2910	2
303	Bacterial Extracellular Vesicles and the Gut-Microbiota Brain Axis: Emerging Roles in Communication and Potential as Therapeutics. 2021 , 5, e2000540	0
302	Molecular and Genetic Factors Involved in Olfactory and Gustatory Deficits and Associations with Microbiota in Parkinson's Disease. 2021 , 22,	3
301	Prodromal Parkinson disease subtypes - key to understanding heterogeneity. 2021 , 17, 349-361	43
300	Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies. 2021 , 9, 62	15
299	Functional amyloids in the microbiomes of a rat Parkinson's disease model and wild-type rats.	
298	Postprandial Increase in Mesenteric Blood Flow is Attenuated in Parkinson's Disease: A Dynamic PC-MRI Study. 2021 , 11, 545-557	1
297	Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. 2021 , 1	13
296	"Janus-Faced" β -Synuclein: Role in Parkinson's Disease. 2021 , 9, 673395	3
295	Patterns of Sulcal depth and cortical thickness in Parkinson's disease. 2021 , 15, 2340-2346	1
294	The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. <i>Neuroscience Letters</i> , 2021 , 753, 135865	3-3 5

293	Mechanistic basis for receptor-mediated pathological β -synuclein fibril cell-to-cell transmission in Parkinson's disease. 2021 , 118,	13
292	Parkinson mice show functional and molecular changes in the gut long before motoric disease onset. 2021 , 16, 34	5
291	The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know. 2021 , 22,	3
290	Impact of the Gut Microbiota Balance on the Health-Disease Relationship: The Importance of Consuming Probiotics and Prebiotics. 2021 , 10,	10
289	Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease. 2021 , 15, 689723	9
288	Vagus Nerve and Stomach Synucleinopathy in Parkinson's Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the "Body-First" Hypothesis. 2021 , 11, 1833-1843	12
287	Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management. 2021 , 11,	1
286	Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease. 2021 , 22,	2
285	Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks. 2021 , 320, C1141-C1152	1
284	Movement of prion-like β -synuclein along the gut-brain axis in Parkinson's disease: A potential target of curcumin treatment. 2021 , 54, 4695-4711	2
283	Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. 2021 , 12, 667066	15
282	Identification of amyloidogenic proteins in the microbiomes of a rat Parkinson's disease model and wild-type rats. 2021 , 30, 1854-1870	1
281	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. 2021 , 11, 1761-1772	3
280	Trojan horses and tunneling nanotubes enable β -synuclein pathology to spread in Parkinson disease. 2021 , 19, e3001331	2
279	Neurodegenerative disorders and gut-brain interactions. 2021 , 131,	10
278	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. 2021 , 8, 655123	2
277	Neuropeptide-S prevents 6-OHDA-induced gastric dysmotility in rats. 2021 , 1762, 147442	1
276	The Neural Gut-Brain Axis of Pathological Protein Aggregation in Parkinson's Disease and Its Counterpart in Peroral Prion Infections. 2021 , 13,	0

275	Role of microbiota-derived short-chain fatty acids in nervous system disorders. 2021 , 139, 111661	21
274	Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough. 2021 , 13, 702639	12
273	Parkinson's Disease and the Gut: Symptoms, Nutrition, and Microbiota. 2021 , 11, 1491-1505	5
272	Enteric glia in homeostasis and disease: From fundamental biology to human pathology. 2021 , 24, 102863	3
271	Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. 2021 , 69, 101347	7
270	Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson's Disease Dementia. 2021 , 11,	1
269	What Is Our Understanding of the Influence of Gut Microbiota on the Pathophysiology of Parkinson's Disease?. 2021 , 15, 708587	2
268	Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats. 2021 , 225, 108746	3
267	Pivotal role of the gut microbiota in congenital insensitivity to pain with anhidrosis. 2021 , 238, 3131-3142	1
266	Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson's Disease. 2021 , 11, 937-947	5
265	GAPDH siRNA Regulates SH-SY5Y Cell Apoptosis Induced by Exogenous β Synuclein Protein. 2021 , 469, 91-102	1
264	Disease-, region- and cell type specific diversity of β Synuclein carboxy terminal truncations in synucleinopathies. 2021 , 9, 146	1
263	Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson's Disease. 2021 , 11, 949-970	3
262	Modeling Parkinson's Disease: Not Only Rodents?. 2021 , 13, 695718	2
261	The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. 2021 , 22,	10
260	Chronic Manganese Exposure and the Enteric Nervous System: An and Mouse Study. 2021 , 129, 87005	2
259	Gut Microbiota as a Potential Player in Mn-Induced Neurotoxicity. 2021 , 11,	3
258	Decrease Associated with Alpha-Synuclein Increase in Muscles of MPTP-Induced Parkinson's Disease Mice. 2021 , 22,	0

257	The Role of Intestinal Macrophages in Gastrointestinal Homeostasis: Heterogeneity and Implications in Disease. 2021 , 12, 1701-1718	5
256	Alpha-Synuclein and the Endolysosomal System in Parkinson's Disease: Guilty by Association. 2021 , 11,	6
255	Structural and Functional Insights into α -Synuclein Fibril Polymorphism. 2021 , 11,	6
254	Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease (the MEDI-PD study): study protocol for a randomised controlled trial. 2021 , 11, e053336	0
253	Parkinson's disease and the gut: Models of an emerging relationship. 2021 , 132, 325-344	1
252	The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?. 2021 , 12, 718220	7
251	A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model. 2021 , 11, 1555-1567	0
250	Association Between Irritable Bowel Syndrome and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. 2021 , 12, 720958	2
249	The antioxidant Rutin counteracts the pathological impact of α -synuclein on the enteric nervous system. 2022 , 403, 103-122	1
248	Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection.. 2022 , 38, 223-244	4
247	Interactions between the microbiota and enteric nervous system during gut-brain disorders. 2021 , 197, 108721	6
246	Non-motor symptoms in Parkinson's disease: Opening new avenues in treatment. 2021 , 2, 100049	2
245	Transcutaneous vagus nerve stimulation (tVNS) as a potential therapeutic application for neurodegenerative disorders - A focus on dysautonomia in Parkinson's disease. 2021 , 235, 102858	0
244	Influence of probiotic bacteria on gut microbiota composition and gut wall function in an model in patients with Parkinson's disease.. 2021 , 3, 100087	7
243	Association between inflammatory bowel diseases and Parkinson's disease: systematic review and meta-analysis. 2022 , 17, 344-353	7
242	Microbiota-Brain-Gut Axis and Neurodegenerative Disorders. 2022 ,	
241	[Therapeutic strategy for Parkinson's disease: targeting zinc-binding protein in astrocytes]. 2021 , 156, 76-80	
240	Disorders of the enteric nervous system - a holistic view. 2021 , 18, 393-410	30

239	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. 2021 , 141, 159-172	28
238	The gut microbiome in neurodegenerative disorders. 2021 , 101-121	
237	References. 2021 , 243-287	
236	αSynuclein Propagation Mouse Models of Parkinson's Disease. 2021 , 2322, 119-130	
235	Opicapone: From Preclinical Data to Real-world Evidence. 2021 , 17, 32	
234	Non-Dopaminergic Pathology of Parkinson's Disease. 15-31	3
233	Modeling Nonmotor Symptoms of Parkinson's Disease in Genetic Mouse Models. 2009 , 483-491	3
232	Mitochondrion- and Endoplasmic Reticulum-Induced SK Channel Dysregulation as a Potential Origin of the Selective Neurodegeneration in Parkinson's Disease. 2012 , 57-79	3
231	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. 2014 , 237-275	2
230	Rotenone as Preclinical Model Compound in Parkinson Disease. 2014 , 995-1012	2
229	Gastric Dysfunction in Parkinson's Disease. 2013 , 145-154	1
228	Nutrition and Gastrointestinal Health as Modulators of Parkinson's Disease. 2014 , 213-242	3
227	Etiology and Pathogenesis of Parkinson's Disease. 2017 , 95-101	3
226	Microbiome and motor neuron diseases. 2020 , 176, 111-122	0
225	Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. 2018 , 14, 40-55	225
224	Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology. 2016 , 6, 30509	42
223	[Structure and efferences of the substantia nigra pars compacta in Parkinson's disease]. 2020 , 88, 591-599	2
222	Functional and molecular early enteric biomarkers for Parkinson's disease in mice and men.	2

221	Vagus Nerve and Stomach Synucleinopathy in Parkinson's Disease, Incidental Lewy Body Disease and Normal Elderly Subjects: Evidence Against the Body-First Hypothesis.	3
220	Experimental colitis drives enteric alpha-synuclein accumulation and Parkinson-like brain pathology.	3
219	Thinking laterally about neurodegenerative proteinopathies. 2013 , 123, 1847-55	80
218	Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. 2010 , 5, e12728	286
217	Differential regional and subtype-specific vulnerability of enteric neurons to mitochondrial dysfunction. 2011 , 6, e27727	24
216	The frequency and severity of gastrointestinal symptoms in patients with early Parkinson's disease. 2014 , 7, 7-12	41
215	Gastrointestinal Autonomic Dysfunction in Patients with Parkinson's Disease. 2015 , 8, 76-82	33
214	Modeling β Synuclein Propagation with Preformed Fibril Injections. 2019 , 12, 139-151	27
213	[The Parkinson puzzle]. 2012 , 153, 2060-9	3
212	[Development of preclinical diagnosis and preventive treatment of neurodegenerative diseases]. 2015 , 115, 4-14	5
211	Protective effect of extract against aging and neurodegeneration. 2020 , 12, 19785-19808	4
210	Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease. 2019 , 26, 3719-3753	23
209	Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson's Disease. 2012 , 6, 1-5	7
208	Sleep deprivation disrupts striatal anti-apoptotic responses in 6-hydroxy dopamine-lesioned parkinsonian rats. 2018 , 21, 1289-1296	1
207	Donepezil for β Synuclein Constipation: An 18 Month Follow-Up. 2018 , 1, 1-4	1
206	Donepezil and β Synuclein Constipation: A 36 Month Follow-Up. 2019 , 1-7	1
205	Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson's Disease. 2020 , 11,	7
204	Neuroprotective Effects of Coffee Bioactive Compounds: A Review. 2020 , 22,	27

203	Toward precision medicine in Parkinson's disease. 2016 , 4, 26	13
202	Leaky gut, dysbiosis, and enteric glia activation: the trilogy behind the intestinal origin of Parkinson's disease. 2020 , 15, 1037-1038	13
201	Predicting Parkinson's Disease and Its Pathology via Simple Clinical Variables. 2021 ,	0
200	Brain regions susceptible to alpha-synuclein spreading. 2021 ,	4
199	The Microbiota-Gut-Brain Axis as a Key to Neuropsychiatric Disorders: A Mini Review. 2021 , 10,	2
198	Parkinson's disease: the nutrition perspective.. 2021 , 1-15	2
197	Disbalance of the duodenal epithelial cell turnover and apoptosis accompanies insensitivity of intestinal redox homeostasis to inhibition of the brain glucose-dependent insulinotropic polypeptide receptors in a rat model of sporadic Alzheimer's disease. 2021 ,	3
196	Lewy pathology of the submandibular gland in Lewy body disease: A report of autopsy cases. 2021 ,	0
195	Cognitive Deficits in Neurodegenerative Disorders: Parkinson's Disease and Alzheimer's Disease. 2011 , 243-292	
194	Gastrointestinal and Swallowing Disturbances in Parkinson's Disease. 257-273	
193	Hereditäre Neuropathien. 2012 , 597-640	
192	Intestinal Dysfunction in Parkinson's Disease. 2013 , 155-171	0
191	Enteric Glial Cells: Implications in Gut Pathology. 2014 , 493-518	
190	Extracellular β synuclein as a Target for Immunotherapy. 2016 , 73-83	
189	Pathological Background of Reduced Cardiac MIBG Uptake. 2017 , 291-311	0
188	Gastrointestinal Dysfunction. 2017 , 101-116	
187	Neurodegenerative Erkrankungen. 2019 , 117-164	1
186	Ogilvie Syndrome Associated to Parkinson's Disease. 2019 , 09, 65-70	

185	Diagnostic potential of gut microbiota in Parkinson's disease. 2020 , 18, 92-101	1
184	The Enteric Glial Network Acts in the Maintenance of Intestinal Homeostasis and in Intestinal Disorders.	1
183	Reduction of Short-Chain Fatty Acid-Producing Gut Microbiota Leads to Transition from Rapid-Eye-Movement Sleep Behavior Disorder to Parkinson's Disease.	0
182	Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease. 2021 , 22,	3
181	Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort. 2021 , 15, 756951	2
180	Physiological and pathological changes in the enteric nervous system of rotenone-exposed mice as early biomarkers for Parkinson's disease.	
179	Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic. 2021 ,	5
178	The Mini Nutritional Assessment (MNA) and applications to Parkinson's disease. 2020 , 597-608	
177	Vagal motoneurons in Parkinson's disease. 2020 , 327-343	0
176	Environmental and genetic risk factors for Parkinson's disease. 2020 , 57-71	
175	Investigating lymphocyte populations in patients with Parkinson's disease. 2020 , 8, 276	1
174	An Update on the Critical Role of α -Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. 2021 , 1	2
173	Neuropathology of Alzheimer's Disease. 2021 ,	11
172	Distribution of α -Synuclein in normal human jejunum and its relations with the chemosensory and neuroendocrine system. 2021 , 65,	1
171	The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders. 2020 , 35, 2150-2155	1
170	Assessment of Neurodegeneration by Optical Coherence Tomography and Mini-Mental Test in Parkinson's Disease. 2019 , 22, 212-216	3
169	Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease. 2021 , 2, 155-191	
168	α -Synuclein pre-formed fibrils induce prion-like protein aggregation and neurotoxicity in <i>C. elegans</i> models of Parkinson's disease.	

167	Neuro-Immunity and Gut Dysbiosis Drive Parkinson's Disease-Induced Pain. 2021 , 12, 759679	0
166	Association Analysis of , and Polymorphisms in Chinese Patients With Parkinson's Disease and Multiple System Atrophy. 2021 , 12, 765833	0
165	Gastrointestinal mucosal biopsies in Parkinson's disease: beyond alpha-synuclein detection. 2021 , 1	0
164	Common Inflammatory Mechanisms in COVID-19 and Parkinson's Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention. 2021 , 14, 6349-6381	11
163	Is the Gut Microbiota a Neglected Aspect of Gut and Brain Disorders?. 2021 , 13, e19740	1
162	TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut. 2021 , 10, 47	2
161	Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors. 2021 , 2, 1-63	
160	Alpha-Synuclein Toxicity: An Insight on Controversial Issues. 2021 , 1-18	
159	A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.. 2022 , e0033820	12
158	Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function.. 2022 , 38, 110090	9
157	Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease.. 2021 ,	3
156	Animal models of brain-first and body-first Parkinson's disease.. 2021 , 163, 105599	3
155	Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease. 2021 , 7, 111	0
154	T cells, β synuclein and Parkinson disease.. 2022 , 184, 439-455	0
153	Metabonomics Combined with 16S rRNA Gene Sequencing to Analyze the Changes of Gut Microbiota in Mice with Parkinson's Disease and the Intervention Effect of Cyanidin-3-O-Glucoside.	
152	Systemic deficiency of GM1 ganglioside in Parkinson's disease tissues and its relation to the disease etiology.. 2022 , 39, 75	1
151	Unconventional secretion of β synuclein mediated by palmitoylated DNAJC5 oligomers.	2
150	Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic.. 2022 , 17, 1462-1467	1

149	Gastrointestinal Dysfunction in Parkinson's Disease.. 2022 , 82, 169	0
148	Air Pollution and the Risk of Parkinson's Disease: A Review.. 2022 ,	2
147	Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics.. 2022 , 12,	2
146	The Key Role of GM1 Ganglioside in Parkinson's Disease.. 2022 , 12,	0
145	Parkinson's Disease in Light of the COVID-19 Pandemic.. 2022 , 12,	3
144	Impact of intestinal disorders on central and peripheral nervous system diseases.. 2022 , 105627	3
143	Serum Uric Acid Levels in Parkinson's Disease: A Cross-Sectional Electronic Medical Record Database Study from a Tertiary Referral Centre in Romania.. 2022 , 58,	0
142	Microbes and Parkinson's disease: from associations to mechanisms.. 2022 ,	1
141	Parkinson's disease: what the model systems have taught us so far. 2018 , 97, 729-751	3
140	Immunotherapeutic interventions in Parkinson's disease: Focus on α Synuclein.. 2022 , 129, 381-433	0
139	Gut microbiota and inflammation in Parkinson's disease: Pathogenetic and therapeutic insights. 2022 , 20, 1721727X2210837	1
138	Chicory: Understanding the Effects and Effectors of This Functional Food.. 2022 , 14,	2
137	Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight.. 2022 , 12,	0
136	Astrocytes expressing Vitamin D-activating enzyme identify Parkinson's disease.. 2022 ,	2
135	Unique Lewy pathology in myotonic dystrophy type 1.. 2022 ,	0
134	Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders.. 2022 , 16, 836605	2
133	Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS.. 2022 , 77, 103908	7
132	Gut-Derived Sterile Inflammation and Parkinson's Disease.. 2022 , 13, 831090	1

131	Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management.. 2022 , 8, 31	4
130	Comparison of commercially available antibodies for the detection of phosphorylated alpha-synuclein in primary culture of ENS.. 2022 , e14354	0
129	Gastrointestinal Disturbances in Parkinson's Disease Including the Management of Sialorrhea. 2022 , 145-154	
128	Central dopaminergic control of cell proliferation in the colonic epithelium.. 2022 ,	1
127	Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo.. 2022 , 12,	2
126	impaired bed mobility in prediagnostic and de novo Parkinson's disease.	
125	Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein.	
124	Gastrointestinal Biopsy Obtained During Cancer Screening, a Biological Marker for Synucleinopathy?. 2022 ,	1
123	The roles of connectivity and neuronal phenotype in determining the pattern of Synuclein pathology in Parkinson's disease.. 2022 , 168, 105687	1
122	The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches.. 2022 , 119243	2
121	MPTP: Advances from an Evergreen Neurotoxin. 2022 , 1-32	
120	Neuropathology and molecular diagnosis of Synucleinopathies.. 2021 , 16, 83	10
119	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. 2021 ,	8
118	Acute Exposure to the Food-Borne Pathogen Does Not Induce Synuclein Pathology in the Colonic ENS of Nonhuman Primates.. 2021 , 14, 7265-7279	0
117	Wilful pathogens provoke a gut feeling in Parkinson's disease.. 2021 , 1	0
116	Comparative diagnostic sensitivity of the substantia nigra transcranial sonography and salivary gland biopsy in patients with Parkinson's disease. 2021 , 40, 101-106	
115	Synucleinopathies. 149-175	
114	Data_Sheet_1.docx. 2020 ,	

113 Table_1.docx. 2020,

112 Table_2.docx. 2020,

111 Table_3.docx. 2020,

110 Data_Sheet_1.PDF. 2020,

109 Data_Sheet_1.ZIP. 2020,

108 Data_Sheet_2.ZIP. 2020,

107 Table_1.docx. 2020,

106 Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson's disease.. 2022, 8, 50 1

105 Toxic trail from the gut to the brain.. 2022,

104 Use of Prebiotics for Addressing Gut Dysbiosis and Achieving Healthy GutBrain Axis. 2022, 207-239

103 Multi-Omics Integration in Mice With Parkinson's Disease and the Intervention Effect of Cyanidin-3--Glucoside.. 2022, 14, 877078 0

102 RNA-based stable isotope probing provides no indication for rapid β synuclein assimilation by murine gut bacteria. 2022, 4,

101 Environmental Neurotoxic Pesticide Exposure Induces Gut Inflammation and Enteric Neuronal Degeneration by Impairing Enteric Glial Mitochondrial Function in Pesticide Models of Parkinson's Disease: Potential Relevance to Gut-Brain Axis Inflammation in Parkinson's Disease Pathogenesis.. 2022, 106225 1

100 Microorganisms associated with increased risk of Parkinson's disease. 2022,

99 Parkinson's Disease Is Associated with Impaired GutBlood Barrier for Short-Chain Fatty Acids. 2

98 Neuroinflammation in Parkinson's Disease [Putative Pathomechanisms and Targets for Disease-Modification. 2022, 13, 3

97 Synuclein Analysis in Adult *Xenopus laevis*. 2022, 23, 6058 0

96 Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease. 2022, 8, 2

95	Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease. 2022 , 12, 739	0
94	Infections and Changes in Commensal Bacteria and the Pathogenesis of Parkinson's Disease. 2022 , 1-7	0
93	Neuroprotective Effects of VEGF in the Enteric Nervous System. 2022 , 23, 6756	1
92	The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease. 14,	
91	Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson's Disease. 2022 , 1-8	2
90	Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease. 13,	1
89	Present and future avenues of cell-based therapy for brain injury: The enteric nervous system as a potential cell source.	1
88	Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.	2
87	Oral and gut dysbiosis leads to functional alterations in Parkinson's disease. 2022 , 8,	1
86	Heparan sulfate proteoglycans mediate prion-like β -synuclein toxicity in Parkinson's in vivo models. 2022 , 5, e202201366	3
85	Inflammasome Activation in Parkinson's Disease. 2022 , 1-16	0
84	Enteric glial cell reactivity in colonic layers and mucosal modulation in a mouse model of Parkinson's disease induced by 6-hydroxydopamine. 2022 , 187, 111-121	0
83	Sensitivity of Detecting Alpha-Synuclein Accumulation in the Gastrointestinal Tract and Tissue Volume Examined.	
82	Identification of gut metabolites associated with Parkinson's disease using bioinformatic analyses. 14,	
81	Multifactor Progression of Parkinson's Disease: Role of Diet and Exposure to Microbiome-Borne Curli.	
80	Donepezil and β -synuclein Constipation: A 60 Month Follow-Up. 2022 , 1-8	
79	Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer's and Parkinson's Disease. 2022 , 10, 1743	0
78	Gut microenvironmental changes as a potential trigger in Parkinson's disease through the gut-brain axis. 2022 , 29,	2

- 77 Lewy Body Disease Primate Model with β -Synuclein Propagation from the Olfactory Bulb. 1
- 76 Antibiotic Consumption Patterns in European Countries Are Associated with the Prevalence of Parkinson's Disease; The Possible Augmenting Role of the Narrow-Spectrum Penicillin. **2022**, 11, 1145
- 75 The absence of gastrointestinal redox dyshomeostasis in the brain-first rat model of Parkinson's disease induced by bilateral intrastriatal 6-hydroxydopamine.
- 74 Rotenone aggravates PD-like pathology in A53T mutant human β -Synuclein transgenic mice in an age-dependent manner. 14, 0
- 73 Microbiota Dysbiosis in Parkinson Disease In Search of a Biomarker. **2022**, 10, 2057 0
- 72 5xFAD mice do not have myenteric amyloidosis, dysregulation of neuromuscular transmission or gastrointestinal dysmotility.
- 71 The relationship between Parkinson's disease and gastrointestinal diseases. 14, 0
- 70 In vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson's disease. **2022**, 103, 23-28 0
- 69 The gut-brain axis in the pathogenesis of Parkinson's disease. **2019**, 5, 73-81 0
- 68 Dopamine and norepinephrine are embracing their immune side and so should we. **2022**, 77, 102626 0
- 67 Intestinal Permeability, Dysbiosis, Inflammation and Enteric Glia Cells: The Intestinal Etiology of Parkinson's Disease. **2022**, 13, 1381 0
- 66 Short-Chain Fatty Acids-A Healthy Bus between Gut Microbiota and Organs beyond the Gut. **2022**, 13, 362-387 0
- 65 Neuroinflammation and Parkinson's Disease From Neurodegeneration to Therapeutic Opportunities. **2022**, 11, 2908 5
- 64 Association between microbiological risk factors and neurodegenerative disorders: An umbrella review of systematic reviews and meta-analyses. 13, 1 1
- 63 Neuronal hyperactivity-induced oxidant stress promotes in vivo β -Synuclein brain spreading. **2022**, 8, 1 1
- 62 Development of neurodegenerative disorders and the role of gut. **2022**, 1, 53-58 0
- 61 Does the Gut Microbial Metabolome Really Matter? The Connection between GUT Metabolome and Neurological Disorders. **2022**, 14, 3967 3
- 60 Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective. 0

59	Adult Neurogenesis in the Gut, Homeostatic Autoimmunity and Neurodegenerative Disease Biomarkers. 2022 ,	1
58	Gangliosides in Neurodegenerative Diseases. 2023 , 391-418	0
57	Presymptomatic neuroanatomical and cognitive biomarkers of alpha-synuclein propagation in a mouse model of synucleinopathy.	0
56	Electroacupuncture Modulates 5-HT4R-Mediated cAMP/PKA Signaling to Improve Intestinal Motility Disorders in a Thy1-Syn Parkinson Mouse Model. 2022 , 2022, 1-13	0
55	Dietary Restriction against Parkinson Disease: What We Know So Far. 2022 , 14, 4108	0
54	Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson Disease. 2022 , 13, 1937	2
53	Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease. 2022 , 23, 13043	1
52	Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism. 14,	0
51	Emerging insights between gut microbiome dysbiosis and Parkinson disease: Pathogenic and clinical relevance. 2022 , 82, 101759	1
50	Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease.	1
49	Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases.	1
48	A combined panel of salivary biomarkers in de novo Parkinson's Disease.	0
47	Persistent intolerable abdominal pain in patients with Parkinson disease. 2023 , 224, 107558	0
46	Parkinson's Disease: Risk Factor Modification and Prevention. 2022 , 42, 626-638	0
45	Externally Validated Deep Learning Model to Identify Prodromal Parkinson Disease from Electrocardiogram.	0
44	Lifelong Constipation in Parkinson Disease and Other Clinically Defined alpha-Synucleinopathies: A Population-Based Study in Southeast Minnesota. 2022 , 105244	0
43	Parasite infections, neuroinflammation, and potential contributions of gut microbiota. 13,	0
42	Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein. 2022 , 12,	0

- 41 Aggregation of alpha-synuclein in enteric neurons does not impact function in vitro. **2022**, 12, 0
- 40 Gut microbiota in dementia with Lewy bodies. **2022**, 8, 0
- 39 Overexpression-Induced β Synuclein Brain Spreading. 1
- 38 High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimer β and Parkinson β disease. 14, 0
- 37 Brain modulation by the gut microbiota: From disease to therapy. **2022**, 1
- 36 Age-Related Decline in Gangliosides GM1 and GD1a in Non-CNS Tissues of Normal Mice: Implications for Peripheral Symptoms of Parkinson β Disease. **2023**, 11, 209 0
- 35 Rotenone-Induced Model of Parkinson β Disease: Beyond Mitochondrial Complex I Inhibition. 1
- 34 Enteric Neurotoxicity and Salsolinol. **2022**, 641-667 0
- 33 C/EBP β /AEP is age-dependently activated in Parkinson β disease and mediates β Synuclein in the gut and brain. **2023**, 9, 0
- 32 Parkinson's disease constipation effect of electroacupuncture at ST25 through colonic motility and enteric neuropathology. 13, 0
- 31 Challenges in the clinical advancement of cell therapies for Parkinson β disease. 0
- 30 Unconventional secretion of β Synuclein mediated by palmitoylated DNAJC5 oligomers. 12, 0
- 29 Neurobiology of depression in Parkinson β disease: Insights into epidemiology, molecular mechanisms and treatment strategies. **2023**, 85, 101840 0
- 28 Cancer in Parkinson β Disease, a Review of Literature. **2021**, 27, 175-183 0
- 27 Asse microbiota-intestino-cervello e neuroinfi ammazione nella patogenesi della malattia di Parkinson. **2022**, 31-44 0
- 26 Upper and lower gastrointestinal symptom association and duration preceding Parkinson β Disease. **2022**, 0
- 25 Animal Models and the Pathogenesis of Parkinson's Disease. **2011**, 113-161 0
- 24 Altered gut microbiota in patients with idiopathic Parkinson β disease: an age β ex matched case β ontrol study. 0

- 23 A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (Line 61) Mice. ○
- 22 Role of rodent models in advancing precision medicine for Parkinson's disease. **2023**, 3-16 ○
- 21 Interneuronal In Vivo Transfer of Synaptic Proteins. **2023**, 12, 569 ○
- 20 Gut-to-Brain α Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms. **2023**, 24, 7205 ○
- 19 Alpha-Synuclein Toxicity: An Insight on Controversial Issues. **2022**, 1489-1506 ○
- 18 MPTP: Advances from an Evergreen Neurotoxin. **2022**, 485-516 ○
- 17 Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool. **2023**, 9, ○
- 16 Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early α Synucleinopathy. ○
- 15 Dysfunction of the noradrenergic system drives inflammation, α Synucleinopathy, and neuronal loss in mouse colon. 14, ○
- 14 The gut microbiome as a factor in the development of Parkinson's disease. **2023**, 15, 90-96 ○
- 13 Tau expression and phosphorylation in enteroendocrine cells. ○
- 12 Machado Joseph disease severity is linked with gut microbiota alterations in transgenic mice. **2023**, 179, 106051 ○
- 11 Infectious Microorganisms Seen as Etiologic Agents in Parkinson's Disease. **2023**, 13, 805 ○
- 10 Alpha Synuclein: Neurodegeneration and Inflammation. **2023**, 24, 5914 ○
- 9 Pink1^{-/-} Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease. ○
- 8 Dysphagia in Parkinson Disease: Part I Pathophysiology and Diagnostic Practices. ○
- 7 α Synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells. ○
- 6 Cognitive heterogeneity in Parkinson's disease: A mechanistic view. **2023**, ○

- 5 Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson Disease. **2023**, 12, 894 ○
- 4 Characterization of Aspirated Duodenal Fluids from Parkinson Disease Patients. **2023**, 15, 1243 ○
- 3 Progesterone: A Neuroprotective Steroid of the Intestine. **2023**, 12, 1206 ○
- 2 Targeting the microbiota-mitochondria crosstalk in neurodegeneration with senotherapeutics. **2023**, ○
- 1 Involvement of Abnormal p-Syn Accumulation and TLR2-Mediated Inflammation of Schwann Cells in Enteric Autonomic Nerve Dysfunction of Parkinson Disease: an Animal Model Study. ○